01—Abstract
Summary
Summary of the 8-K filed January 12, 2026. Cited figures are marked; the original filing is the authoritative source.
Edwards Lifesciences (EW) disclosed in an 8-K filed January 12, 2026 that the U.S. District Court for the District of Columbia granted the Federal Trade Commission's motion for a preliminary injunction blocking Edwards' proposed acquisition of JenaValve Technology, Inc. As a result, Edwards will not complete the deal.
The company publicly disagreed with the decision, arguing the acquisition would have served a large, growing, and underserved patient population with aortic regurgitation (AR), a condition it describes as under-detected, under-referred, and highly lethal if untreated. The strategic implication is that Edwards loses a direct route into the AR valve market, and it will need to rely on its internal programs, principally the SOJOURN transcatheter AR valve and the pivotal JOURNEY trial, to address that segment. The filing does not quantify any termination fee, deal costs, or write-offs, so investors should look to upcoming disclosures for the financial impact of the abandoned transaction.
On the financial side, Edwards raised its full-year 2026 adjusted diluted EPS guidance to $2.90a–$3.05 from $2.80–$2.95, a range that is roughly $0.10 higher at both ends. The company said further updates would come at its fourth-quarter earnings call in February. Adjusted EPS excludes litigation expenses, intangible amortization, impairment losses, and separation costs, and the company does not reconcile this non-GAAP guidance to GAAP.
02—Key points
Key Highlights
- Federal court granted the FTC's motion for an injunction blocking Edwards' proposed acquisition of JenaValve Technology, so the deal will not close.
- Edwards disagrees with the ruling and maintains that the acquisition would have benefited patients with aortic regurgitation.
- The company is raising its FY2026 adjusted diluted EPS guidance to $2.90–$3.05 from $2.80–$2.95, an increase of about $0.10 at both ends of the range.
- Edwards is continuing to advance its own AR program, including the SOJOURN transcatheter AR valve and enrollment in the JOURNEY pivotal trial.
- The filing does not disclose termination fees, transaction costs, or accounting charges related to the terminated deal.
- Further guidance updates are expected at the Q4 2025 earnings call in February 2026.
- The guidance raise is on an adjusted (non-GAAP) basis, and the company does not provide a GAAP reconciliation.
03—Questions
Frequently Asked Questions
Why did the acquisition of JenaValve fail?
The U.S. District Court for the District of Columbia granted the FTC's motion for an injunction blocking the deal. The FTC challenged the transaction on antitrust grounds, and the court's ruling means Edwards cannot complete the acquisition.
Why is Edwards raising its 2026 EPS guidance if it lost a deal?
The company attributes the revised guidance to the update on the JenaValve transaction. The filing does not explain the mechanics, so investors should review the February earnings call for the full rationale, since the change is modest, about $0.10 per share at both ends of the range.
What does Edwards plan to do in aortic regurgitation now?
Edwards says it remains committed to leading AR therapy. It plans to advance the SOJOURN transcatheter AR valve and continue enrolling patients in the JOURNEY pivotal trial, with its own internal development replacing the planned acquisition.
Are there financial costs from the terminated deal?
The 8-K does not disclose any termination fee, deal expenses, or impairment charges. Investors should watch for these in the company's upcoming quarterly reports and earnings call, since the adjusted EPS definition excludes litigation expenses and separation costs.
What is the difference between the adjusted and GAAP guidance?
Adjusted EPS is a non-GAAP measure that excludes certain litigation expenses, amortization of intangible assets, impairment losses, and separation costs. Edwards does not provide a reconciliation to GAAP EPS because it cannot reliably forecast these items, so the guidance may differ materially from GAAP results.
04—Continue